3692:HKEXHansoh Pharmaceutical Group Company Limited Analysis
Data as of 2026-03-12 - not real-time
HK$34.92
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Hansoh Pharmaceutical trades at HK$34.92, sitting just below its 20‑day SMA (35.00) and well under its 50‑day SMA (37.52), indicating a modest short‑term pullback despite a bullish MACD histogram (+0.14) and rising volume. Fundamentally, the company posts a 14% revenue growth rate, 90% gross margin, and a solid cash pile of HK$27.1 bn, while its dividend payout ratio sits at 38%, suggesting dividend sustainability.
However, the stock’s PE of 38.8 far exceeds the industry average of 26.7 and the DCF‑derived fair value of HK$18.5, flagging a clear overvaluation risk. The high 30‑day volatility (≈37%) and a max drawdown of 26% add to the caution, even though beta is slightly negative, implying limited market correlation.
However, the stock’s PE of 38.8 far exceeds the industry average of 26.7 and the DCF‑derived fair value of HK$18.5, flagging a clear overvaluation risk. The high 30‑day volatility (≈37%) and a max drawdown of 26% add to the caution, even though beta is slightly negative, implying limited market correlation.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hovering below short‑term moving averages
- Bullish MACD histogram with increasing volume
- Elevated valuation relative to peers
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Robust revenue growth and high profitability margins
- Strong cash generation and low leverage
- Analyst consensus of strong‑buy with target median price ~HK$46.4
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Sustainable dividend yield and payout ratio
- Long‑term pipeline partnerships with GSK, Merck, and Biotheus
- Overvaluation concerns tempered by solid fundamentals and defensive sector positioning
Key Metrics & Analysis
Financial Health
Revenue Growth14.30%
Profit Margin36.25%
P/E Ratio38.8
ROE16.21%
ROA8.35%
Debt/Equity0.38
P/B Ratio5.9
Op. Cash FlowHK$4.8B
Free Cash FlowHK$3.3B
Industry P/E26.7
Technical Analysis
TrendNeutral
RSI46.9
SupportHK$31.58
ResistanceHK$38.38
MA 20HK$35.00
MA 50HK$37.52
MA 200HK$35.70
MACDBullish
VolumeIncreasing
Fear & Greed Index78.16
Valuation
Fair ValueHK$18.46
Target PriceHK$46.51
Upside/Downside33.20%
GradeOvervalued
TypeGrowth
Dividend Yield1.38%
Risk Assessment
Beta-0.12
Volatility37.18%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.